"cell line mcf 7" trang 9 - tải miễn phí từ tailieunhanh
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first line tyrosine kinase inhibitors: Brain metastasis and de novo T790M matters

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first line tyrosine kinase inhibitors: Brain metastasis and de novo T790M matters
11    21    1
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMACNS trial

Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMACNS trial
10    1    1
Efficacy and safety of fuzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: A multi-center, single-arm prospective phase II clinical study (STAMP study)

Efficacy and safety of fuzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: A multi-center, single-arm prospective phase II clinical study (STAMP study)
11    1    1
Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving frst-line immunotherapy: A multicenter retrospective study

Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving frst-line immunotherapy: A multicenter retrospective study
21    1    1
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
13    4    1
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
8    2    1
Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: A modelling approach

Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: A modelling approach
10    7    1
Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: A systematic review and meta-analysis of clinical characteristics

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: A systematic review and meta-analysis of clinical characteristics
17    7    1
Baseline C-reactive protein predicts efcacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: A retrospective, multicenter study

Baseline C-reactive protein predicts efcacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: A retrospective, multicenter study
10    1    1
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
6    8    1
Self-assembled DNA nanostructure containing oncogenic miRNA-mediated cell proliferation by downregulation of FOXO1 expression

Self-assembled DNA nanostructure containing oncogenic miRNA-mediated cell proliferation by downregulation of FOXO1 expression
10    1    1
Phase II study of carboplatin/nab-paclitaxel/ atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Phase II study of carboplatin/nab-paclitaxel/ atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
5    1    1
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial
9    1    1
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFRmutated non-small cell Lung cancer with brain metastases: A systematic review and meta-analysis

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFRmutated non-small cell Lung cancer with brain metastases: A systematic review and meta-analysis
11    3    1
Báo cáo y học:

Báo cáo y học: " Isolation of suppressor genes that restore retrovirus susceptibility to a virus-resistant cell line"
10    49    0
Báo cáo y học:

Báo cáo y học: " The establishment and characterization of the first canine hepatocellular carcinoma cell line, which resembles human oncogenic expression patterns"
10    38    0
Báo cáo y học:

Báo cáo y học: " Cell line-dependent variability in HIV activation employing DNMT inhibitors"
10    37    0
Hydroxyurea for the Treatment of Sickle Cell Disease

Hydroxyurea for the Treatment of Sickle Cell Disease

298    106    0
Báo cáo khoa học:

Báo cáo khoa học: " Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2"
10    49    0
Báo cáo khoa học:

Báo cáo khoa học: " Enhanced detection and study of murine norovirus-1 using a more efficient microglial cell line"
7    42    0